Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23140220 | 0.87 | KCNH2 (0.42) | KCNH2LTB4RNOS1NOS2NPSR1 | |
| SCHEMBL10141737 | 0.86 | KCNH2 (0.56) | KCNH2LTB4RNOS1NOS2HIF1A | |
| SCHEMBL6069599 | 0.84 | KCNH2 (0.76) | KCNH2LTB4R | |
| SCHEMBL23278570 | 0.84 | KCNH2 (0.63) | KCNH2LTB4RNOS1NOS2NPSR1 | |
| SCHEMBL3625374 | 0.82 | GABRA1 (0.44) | KCNH2NOS1NOS2NPSR1GABRA1 | |
| SCHEMBL18924306 | 0.79 | KCNH2 (0.52) | KCNH2LTB4RNOS1NOS2NPSR1 | |
| SCHEMBL18858526 | 0.78 | KCNH2 (0.48) | KCNH2NOS1NOS2NPSR1SYK | |
| SCHEMBL23106424 | 0.78 | KCNH2 (0.41) | KCNH2NOS1NOS2NPSR1GABRA1 | |
| SCHEMBL19862547 | 0.76 | KCNH2 (0.44) | KCNH2NOS1NOS2NOS3 | |
| SCHEMBL19862536 | 0.75 | KCNH2 (0.43) | KCNH2NOS1NOS2HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNH2 3887/4885LTB4R 1828/4885NOS1 1084/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | KCNH2 3887/4885LTB4R 1828/4885NOS1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.